WO2005058845A3 - Nouveaux antagonistes/agonistes inverses du glucagon - Google Patents

Nouveaux antagonistes/agonistes inverses du glucagon Download PDF

Info

Publication number
WO2005058845A3
WO2005058845A3 PCT/EP2004/053580 EP2004053580W WO2005058845A3 WO 2005058845 A3 WO2005058845 A3 WO 2005058845A3 EP 2004053580 W EP2004053580 W EP 2004053580W WO 2005058845 A3 WO2005058845 A3 WO 2005058845A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
cycloalkenyl
heteroaryl
cycloalkyl
Prior art date
Application number
PCT/EP2004/053580
Other languages
English (en)
Other versions
WO2005058845A2 (fr
Inventor
Peter Madsen
Jesper Lau
Janos Tibor Kodra
Inge Thoeger Christensen
Original Assignee
Novo Nordisk As
Peter Madsen
Jesper Lau
Janos Tibor Kodra
Inge Thoeger Christensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Peter Madsen, Jesper Lau, Janos Tibor Kodra, Inge Thoeger Christensen filed Critical Novo Nordisk As
Publication of WO2005058845A2 publication Critical patent/WO2005058845A2/fr
Publication of WO2005058845A3 publication Critical patent/WO2005058845A3/fr
Priority to US11/424,871 priority Critical patent/US20070015757A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

L'invention concerne de nouveaux composés qui ont un effet antagoniste sur l'action de l'hormone peptidique du récepteur du glucagon. Plus particulièrement, l'invention concerne des antagonistes ou des agonistes inverses du glucagon.
PCT/EP2004/053580 2003-12-19 2004-12-17 Nouveaux antagonistes/agonistes inverses du glucagon WO2005058845A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/424,871 US20070015757A1 (en) 2003-12-19 2006-06-18 Novel Glucagon Antagonists/Inverse Agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301894 2003-12-19
DKPA200301894 2003-12-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/424,871 Continuation US20070015757A1 (en) 2003-12-19 2006-06-18 Novel Glucagon Antagonists/Inverse Agonists

Publications (2)

Publication Number Publication Date
WO2005058845A2 WO2005058845A2 (fr) 2005-06-30
WO2005058845A3 true WO2005058845A3 (fr) 2005-10-20

Family

ID=34684453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/053580 WO2005058845A2 (fr) 2003-12-19 2004-12-17 Nouveaux antagonistes/agonistes inverses du glucagon

Country Status (1)

Country Link
WO (1) WO2005058845A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250826A1 (en) * 2004-03-26 2005-11-10 Thais Sielecki-Dzurdz Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
EP2001472A2 (fr) 2006-03-23 2008-12-17 Merck and Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
CA2650619A1 (fr) 2006-05-16 2007-11-29 Merck And Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant ces composes, et procedes d'utilisation
BRPI0816258B8 (pt) 2007-09-10 2022-12-27 Mitsubishi Tanabe Pharma Corp processo para a preparação de compostos úteis como inibidores de sglt
MY156381A (en) 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2010039789A1 (fr) * 2008-10-03 2010-04-08 Schering Corporation Dérivés de spiro-imidazolone utilisés en tant qu'antagonistes des récepteurs du glucagon
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
SI2488515T1 (sl) 2009-10-14 2017-04-26 Janssen Pharmaceutica Nv Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
KR101778617B1 (ko) * 2010-11-30 2017-09-15 에스케이유화 주식회사 메틸-4-히드록시이미노메틸벤조에이트의 제조방법
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
JP5562495B2 (ja) 2011-02-08 2014-07-30 ファイザー・インク グルカゴン受容体モジュレーター
EP2697218B1 (fr) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000612A1 (fr) * 2000-06-23 2002-01-03 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040444A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
WO2002040446A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2004056763A2 (fr) * 2002-12-20 2004-07-08 Novo Nordisk A/S Nouveaux antagonistes du glucagon
US20040209928A1 (en) * 2002-12-30 2004-10-21 Ravi Kurukulasuriya Glucagon receptor antagonists/inverse agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000612A1 (fr) * 2000-06-23 2002-01-03 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2002040444A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
WO2002040446A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
WO2004056763A2 (fr) * 2002-12-20 2004-07-08 Novo Nordisk A/S Nouveaux antagonistes du glucagon
US20040209928A1 (en) * 2002-12-30 2004-10-21 Ravi Kurukulasuriya Glucagon receptor antagonists/inverse agonists

Also Published As

Publication number Publication date
WO2005058845A2 (fr) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2005058845A3 (fr) Nouveaux antagonistes/agonistes inverses du glucagon
SE0500709L (sv) Roterande gruvborrkrona för att göra spränghål
DE602004020640D1 (de) Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxyhept-6-ensäureü-calciumsalz
EA200602170A1 (ru) Производные пиперидина, композиции на их основе, способы их применения
WO2004066920A3 (fr) Derives cortisol de 17-carbamoyloxy utilises en tant que modulateurs selectifs des recepteurs aux glucocorticoides
NO20035849L (no) Nye vevsfaktorrettede trombomodulinfusjonsproteiner som antikoagulanter
PE27299A1 (es) Piridinas sustituidas utiles como inhibidores selectivos de ciclooxigenasa 2
EA202190654A1 (ru) Гетероциклическое соединение
MXPA04012691A (es) Derivados de azabiciclo-octano y nonano con actividad inhibitoria de dpp-iv.
PT1592793E (pt) Compostos oligoméricos para a modulação da expressão de survivina
EA200602019A1 (ru) Производные пиперазина и их применение для борьбы с вредителями
DK1781697T3 (da) Nyt carbamyleret erythropoietinprotein samt fremstillingsmetode
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
PE20050090A1 (es) Indol-3-carboxamidas como activadores de glocoquinasa
ATE452882T1 (de) Herstellung von quetiapin
WO2008093674A1 (fr) Nouveau dérivé de thiadiazole ayant une activité inhibitrice de la kinase
WO2004074247A3 (fr) Antagonistes du recepteur de l'adenosine a1
NO20052663D0 (no) Partikkel med langstrakt form, anvendelse derav som en katalysator eller baerer
ZA200501740B (en) Vector for the production of transplastomic angiosperm plants.
EA201291376A1 (ru) Новые кальциевые соли соединения в качестве противовоспалительных, иммуномодулирующих и антипролиферативных агентов
FI20030030A0 (fi) Uusia yhdisteitä
FI20010293A0 (fi) Menetelmä turvattujen yhteyksien luomiseen
AU2003291959A1 (en) Novel glucagon antagonists
ITRM20030489A1 (it) Impianto di produzione energetica dallo sfruttamento di
PE20081683A1 (es) Nuevos derivados de sulfonamida

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11424871

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11424871

Country of ref document: US

122 Ep: pct application non-entry in european phase